INS and Hypoglycemia: The HypoAna trial showed that although the total cost was larger for treatment with insulin analogs, the analog regimen was considered more cost-effective than the human insulin regimen during 1 year of treatment due to lower rates of severe and nocturnal hypoglycemia (Pedersen-Bjergaard et al., 2016).